Last reviewed · How we verify
DaunoXome
DaunoXome is a liposomal formulation of daunorubicin that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cells.
DaunoXome is a liposomal formulation of daunorubicin that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cells. Used for Advanced HIV-associated Kaposi sarcoma, Acute leukemias (in combination regimens).
At a glance
| Generic name | DaunoXome |
|---|---|
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Drug class | Liposomal anthracycline chemotherapy |
| Target | DNA (topoisomerase II inhibitor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
DaunoXome encapsulates the anthracycline chemotherapy agent daunorubicin within liposomes, which preferentially accumulate in tumor tissues and inflamed areas due to enhanced permeability and retention. The daunorubicin intercalates into the DNA double helix and inhibits topoisomerase II, preventing DNA unwinding and causing double-strand breaks that trigger apoptosis in cancer cells. The liposomal formulation reduces cardiotoxicity and systemic toxicity compared to conventional daunorubicin.
Approved indications
- Advanced HIV-associated Kaposi sarcoma
- Acute leukemias (in combination regimens)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Cardiotoxicity (reduced vs. conventional daunorubicin)
- Infusion reactions
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DaunoXome CI brief — competitive landscape report
- DaunoXome updates RSS · CI watch RSS
- Gruppo Italiano Malattie EMatologiche dell'Adulto portfolio CI